Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
H., & Rubino, D
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Functional assessment Reduced or absent expected effects provide the most definitive degradation evidence but require prior experience with functional product
The STEP (Semaglutide Treatment Effect in People with Obesity) trials represent the most comprehensive safety data available for semaglutide at the 2.4 mg weight loss dose
The peptide is supplied in lyophilized form to preserve stability during storage and transport, supporting reliable performance in receptor signaling assays, biochemical investigations, and other controlled laboratory research applications
US$ 29.44
US$ 27.33
US$ 27.11
US$ 20.03
US$ 25.10
US$ 25.20
US$ 20.31
US$ 27.39
00656-2/asset/35b48abc-e313-46be-9a87-b6727032b3d4/main.assets/gr1_lrg.jpg)
US$ 28.30
